The partnership will develop differentiated cancer vaccine candidates for certain hematological and solid tumors with high unmet medical needs, according to an April 16 company news release. Both parties will contribute to identifying differentiated cancer antigens based on whole genome sequencing. The most promising vaccine candidates will go through initial phase 1 and 2 studies led by MD Anderson.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
